Drug giant Pfizer (PFE) is in buying range after getting a boost from a better-than-expected quarterly earnings report. The maker of blockbuster drugs such as Viagra and cholesterol fighter Lipitor broke out past a 35.63 buy point of a flat base in heavy volume on Wednesday. It remains within the 5% limit that defines a buy range.